Supplementary Figure S7 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies

Supplemental Figure S7: XTX301 caused transient and reversible changes to LFTs and other safety parameters in NHP in a repeat dose GLP toxicology study. Male and female NHPs (N=3/sex; 2/sex for recovery animals) were administered XTX301 by intravenous infusion once weekly for a total of four doses, followed by a four-week recovery period. Changes in (a) aspartate aminotransferase, (b) alanine aminotransferase, (c) total lymphocytes, (d) albumin, and (e) IFN- were fully reversible in the main study and recovery animals. All values are shown as mean ± SD. The reference ranges, indicated by the grey-shaded area, were derived from the study facility’s historical control values.